Biotechnology

As CFO Scott Ullem preps for a key presentation, Edwards balances record innovation and strong financials against new regulatory hurdles. What's at stake?

Early clinical results for MP0712, a novel Radio-DARPin, suggest a breakthrough for targeting aggressive cancers like SCLC while sparing healthy tissue.

NurExone appoints Eyal Gabbai, a healthcare and finance heavyweight, to its board, signaling a strategic pivot from R&D to market execution for its therapies.

Shane Kovacs's exit from Olema Oncology introduces leadership questions as the biotech firm nears a pivotal data readout for its lead breast cancer drug.

Tevogen Bio's stock surged on news of a potential special dividend, but a closer look reveals a risky promise from a pre-revenue firm facing major hurdles.

Incyte's Zynyz gets a key EU panel's nod, offering a breakthrough for advanced anal canal cancer patients after decades of limited treatment options.

After selling its proteomics arm to Illumina for $350M+, Standard BioTools is flush with cash but faces a pivotal moment to fix its core business.

With a major cash infusion, NeOnc Technologies is set to accelerate its promising therapies aimed at conquering the elusive blood-brain barrier.

Known for non-opioid pain relief, Scilex is diversifying with a major investment in a stealthy diagnostic firm, hinting at a new data-driven strategy.

Ruxolitinib cream's landmark approval in China marks a new era for vitiligo treatment, impacting patients, markets, and regulatory policy.

CIRM's new RAPID program aims to revolutionize genetic therapy, using scalable platforms to bring hope to millions with rare diseases who have no options.

Facing a cash crunch after a major clinical trial setback, the cancer vaccine developer is exploring a sale or merger, putting its pipeline at risk.

A $10M investment from pharma giant Dr. Reddy’s validates Coya Therapeutics' novel ALS drug, funding the path to commercial-scale manufacturing.

Following the departure of its R&D head, Immunocore streamlines leadership, betting on internal experts to drive its next wave of innovative therapies.

With stronger Phase 2 data for its ATH434 drug and a healthy cash reserve, Alterity Therapeutics is preparing for a pivotal trial and seeking partners.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.

The global fitness giant is exploring a Wall Street listing and launching a DNA-based longevity program, signaling a major push for market leadership.

A new global survey reveals millions of women are unprepared for menopause's skin impact. One company is now pushing for a new standard in research.

New data on Idorsia's lucerastat reveals potential to slow kidney decline in Fabry disease, offering a new path for an oral, genotype-independent therapy.

A groundbreaking implantable cell therapy shows consistent, positive results for a debilitating complication of Crohn's disease, paving an expedited path to market.